RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating patients with recurrent or metastatic bladder cancer.
OBJECTIVES: I. Determine the response rate and toxic effects of continuous fluorouracil in patients with recurrent locally advanced or metastatic transitional cell urinary tract carcinoma. II. Determine the feasibility of this treatment in this patient population. OUTLINE: Patients receive continuous intravenous fluorouracil by a Baxter Infusor for 24 weeks. Patients are evaluated for complete and partial response at 8, 16, and 24 weeks after the start of intravenous fluorouracil. Patients experiencing disease progression or unacceptable toxic effects are removed from the study. Patients are followed monthly for 6 months post treatment. PROJECTED ACCRUAL: A maximum of 45 patients will be accrued.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
45
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Porto Alegre Hospital
Porto Alegre, Rio Grande do Sul, Brazil
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada
Mount Sinai Hospital - Toronto
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Hopital Sainte Justine
Montreal, Quebec, Canada
Maria Hospital
Helsinki, Finland
Antoni van Leeuwenhoekhuis
Amsterdam, Netherlands
Christchurch Hospital
Christchurch, New Zealand
Norwegian Radium Hospital
Oslo, Norway
Groote Schuur Hospital, Cape Town
Cape Town, South Africa
...and 52 more locations